Recently, the EMPA-REG outcomes trial investigated the effects of empagliflozin, another SGLT2 inhibitor [17], and reported that empagliflozin significantly reduced the all-cause and cardiovascular mortality rates and the rate of hospitalization for heart failure compared to placebo in T2DM patients with high cardiovascular risk [17]. This evidence concerns the gene SLC5A2 and heart failure.